Conditions: Parkinson's Disease
Keywords: Rotigotine patch Neupro Parkinson's Disease
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 57
Healthy volunteers: no

Brief summary:
The primary objective of the study is to compare the adhesiveness of 2 different patch formulations of Rotigotine using the largest patch size of 40 cm\^2, under the assumption that both patch formulations show similar adhesiveness properties.

Detailed description:

Arms:
arm 1: 4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1) arm 2: 4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1)

Interventions: intervention 1: Rotigotine (Test product PR 2.3.1) intervention 2: Rotigotine (Reference product PR 2.1.1)
Intervention descriptions: intervention 1: * Pharmaceutical form: Transdermal patch
* Concentration: 8 mg/24 hours
* Route of administration: Transdermal intervention 2: * Pharmaceutical form: Transdermal patch
* Concentration: 8 mg/24 hours
* Route of administration: Transdermal

Protocol document: